Electropharmacological effects of UK-1745, a novel cardiotonic drug, in guinea-pig ventricular myocytes

European Journal of Pharmacology

Volumn 383, Issue 3, 1999, Pages 361-371

  Uemura, Hiroko ^a   Sakamoto, Naoya ^a   Nakaya, Haruaki ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ca2+ channel; Cardiotonic drug; Milrinone; UK 1745

Indexed keywords

2 AMINOMETHYL 2,3,7,8 TETRAHYDRO 2,3,5,8,8 PENTAMETHYL 6H FURO[2,3-E]INDOL 7 ONE; CALCIUM CHANNEL; CARDIOTONIC AGENT; CYCLIC AMP; HISTAMINE; ISOPRENALINE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GUINEA PIG; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HEART VENTRICLE WALL; INOTROPISM; MEMBRANE CURRENT; NONHUMAN; PRIORITY JOURNAL;

ACTION POTENTIALS; ANIMALS; CARDIOTONIC AGENTS; GUINEA PIGS; HEART VENTRICLES; INDOLES; MILRINONE; PAPILLARY MUSCLES; PHOSPHODIESTERASE INHIBITORS;

EID: 0032786686     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00651-2     Document Type: Article

References (43)

1. Brunkhorst D., Leyden H., Meyer W., Nigbur R., Schmidt-Schumacher C., Scholz H. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG212CI, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea pig heart. Naunyn-Schmiedeberg's Arch. Pharmacol. 339:1989;575-583.
2. Charlap S., Lichstein E., Frishman W.H. β-Adrenergic blocking drugs in the treatment of congestive heart failure. Med. Clin. North Am. 73:1989;373-385.
3. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 90:1994;1665-1673.
4. Epstein S.E., Braunwald E. The effects of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann. Intern. Med. 65:1966;20-27.
5. 2+ sensitizer, in guinea pig atrial cells. Cardiovasc. Res. 38:1998;685-694.
6. Fabiato A., Fabiato F. Calculator programs for computing the composition of solution containing multiple metals and legend used for experiments in skinned muscle cells. J. Physiol. (Paris). 75:1979;463-505.
7. Fischmeister R., Hartzell H.C. Regulation of calcium current by low-Km cyclic AMP phosphodiesterases in cardiac cells. Mol. Pharmacol. 38:1990;426-433.
8. 2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ. Res. 63:1988;911-922.
9. Hamill O.P., Marty A., Neher E., Sakmann B., Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch. 391:1981;85-100.
10. Hara Y., Nakaya H. SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells. Br. J. Pharmacol. 116:1995;2750-2756.
11. Hashimoto K., Mitsuhashi H. Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias. Br. J. Pharmacol. 88:1986;915-921.
12. 2+ current. Pflügers Arch. 410:1987;23-29.
13. Hosokawa T., Mori T., Fujiki H., Kinoshita S., Takemoto K., Imaizumi T., Noda T., Ohura M., Tominaga M., Yabuuchi Y. Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action. Heart Vessels. 7:1992;66-75.
14. Isenberg G., Klockner U. Calcium tolerant ventricular myocytes prepared by preincubation in a "KB medium" Pflügers Arch. 395:1982;6-18.
15. Kameyama M., Hofmann F., Trautwein W. On the mechanism of β-adrenergic regulation of the Ca channel in the guinea-pig heart. Pflügers Arch. 405:1985;285-293.
16. Kawada M., Sawanobori K., Sonoki H., Inoue K., Mizuno K., Itou T., Kyoutani Y., Uchida Y. Cardiovascular effects of furo[2,3-e]indole derivative UK-1745, a novel cardiotonic agent. Jpn. J. Pharmacol. 71(Suppl. I):1996;. 229 pp.
17. Kirstein M., Rivet-Bastide M., Hatem S., Benardeau A., Mercadier J.J., Fischmeister R. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J. Clin. Invest. 95:1995;794-802.
18. Lawson J.W. Antiarrhythmic activity of some isoquinoline derivatives determined by a rapid screening procedure in the mouse. J. Pharmacol. Exp. Ther. 160:1968;22-31.
19. Malecot C.O., Bers D.M., Katzung B.G. Biphasic contractions induced by milrinone at low temperature in ferret ventricular muscle: role of the sarcoplasmic reticulum and transmembrane calcium influx. Circ. Res. 59:1986;151-162.
20. Nakaya H., Tohse N., Takeda Y., Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br. J. Pharmacol. 109:1993;157-163.
21. Packer M., Medira N., Yushak M. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation. 70:1984;1038-1047.
22. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., Zeldis S.M., Hendrix G.H., Bommer W.J., Elkayam U., Kukin M.L., Mallis G.I., Sollano J.A., Shannon J., Tandon P.K., DeMets D.L. Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 325:1991;1468-1475.
23. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334:1996;1349-1355.
24. Piwonka R.W., Healey J.F., Caniff P.C., Farah A.E. Electrophysiological actions of amrinone in dogs with cardiac lesions. J. Cardiovasc. Pharmacol. 5:1983;1052-1057.
25. Ravens U., Flüß M.O., Li Q., Himmel H.M., Wettwer E., Klocknow M., Lues I. Stereoselectivity of actions of the calcium sensitizer [+]-EMD60263 and its enantiomer [-]-EMD60264. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;733-742.
26. Reddy S., Benatar D., Gheorghiade M. Update on digoxin and other oral positive inotropic agents for chronic heart failure. Curr. Opin. Cardiol. 12:1997;233-241.
27. Satoh H., Hashimoto K. Effect of 3,4-dihydro-6[4-(3,4-dimethoxy-benzoyl)-1-piperazyl]-2(1H)-quinolinone (OPC-8212) on the membrane currents of rabbit sino-atrial node. Arzneim.-Forsch. 34:1984;376-380.
28. Sawada H., Endoh M. Pharmacological characterization of effects of UK-1745, a novel cardiotonic agent with β-adrenoceptor-blocking action, in aequorin-loaded canine right ventricular muscle. J. Mol. Cell. Cardiol. 31:1999;1047-1052.
29. Shakar S.F., Abraham W.T., Gilbert E.M., Rabertson A.D., Lowes B.D., Zisman L.S., Ferguson D.A., Bristow M.R. Combined oral positive inotropic and beta-blocker therapy for treatment of class IV heart failure. J. Am. Coll. Cardiol. 31:1998;1336-1340.
30. Sutko J.L., Kenyon J.L., Reeves J.P. Effects of amrinone and milrinone on calcium influx into the myocardium. Circulation. 73:1986;11152-11158.
31. Tada M., Katz A.M. Phosphorylation of the sarcoplasmic reticulum and sarcolemma. Annu. Rev. Physiol. 44:1982;401-423.
32. + current by histamine in guinea pig ventricular myocytes. Naunyn-Schmiedeberg's Arch. Pharmacol. 344:1991;582-588.
33. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316:1987;1429-1435.
34. + current of guinea pig ventricular cells through the activation of protein kinase C. Circ. Res. 71:1992;1441-1446.
35. Tsien R.Y., Rink T.J. Neutral carrier ion-sensitive microelectrode for measurement of intracellular calcium. Biochem. Biophys. Acta. 599:1980;623-638.
36. Uchida Y., Kawada M., Sawanobori K., Sonoki H., Inoue K., Mizuno K., Itou T., Takunoki Y., Tsukamoto M., Ohashi Y., Kyoutani Y., Shimizu N., Fujii M., Nakamura M. Cardiovascular effects of (2RS,3SR)-2-aminomethyl-2,3,7,8-tetrahydro-2,3,5,8,8-pentamethyl-6H-furo-[2,3-e] indol-7-one hydrochloride (UK-1745), a novel cardiotonic agent with vasodilatory and antiarrhythmic properties. Arzneim.-Forsch. 48:1998;219-231.
37. Uchida Y., Sonoki H. Effect of UK-1745, a novel furoindole derivative with both cardiotonic and antiarrhythmic actions, on chronic congestive heart failure in dogs. Jpn. J. Pharmacol. 71(Suppl. I):1996;. 227 pp.
38. Uretsky B.F., Jessup M., Konstam M.A., William G., Leier C.V., Benotti J., Murali S., Herrmann H.C., Sandberg J.A. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation. 82:1990;774-780.
39. van Zwieten P.A. Current and newer approaches in the drug treatment of congestive heart failure. Cardiovasc. Drugs Ther. 10:1996;693-702.
40. Varró A., Papp J.G. Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizer be placed? J. Cardiovasc. Pharmacol. 26(Suppl 1):1995;S32-S44.
41. Waagstein F., Bristow M.R., Swedberg K., Camerini F., Fowler M.B., Silver M.A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 342:1993;1441-1446.
42. Yazawa K., Abiko Y. Modulation by histamine of the delayed outward potassium current in guinea-pig ventricular myocytes. Br. J. Pharmacol. 109:1993;142-147.
43. Yazawa K., Kameyama M. Mechanism of receptor-mediated modulation on the delayed outward potassium current in guinea-pig ventricular myocytes. J. Physiol. (London). 421:1990;135-150.